Albireo Pharma, Inc.
NASDAQ: ALBO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ronald H. W. Cooper
- Employees
- 130
- Headquarters
- Boston, United States
- IPO year
- 2007
- Market cap
- $915.9M
- Website
- https://www.albireopharma.com
Loading ALBO…
Loading profile data…Frequently asked questions about ALBO
What does Albireo Pharma, Inc. (ALBO) do?
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a t...
Where does ALBO trade?
Albireo Pharma, Inc. (ALBO) trades on the NASDAQ Capital Market.
What sector is ALBO in?
Albireo Pharma, Inc. (ALBO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Albireo Pharma, Inc.?
Ronald H. W. Cooper is the chief executive officer of Albireo Pharma, Inc. (ALBO).
Where is Albireo Pharma, Inc. headquartered?
Albireo Pharma, Inc. is headquartered in United States.
Does ALBO pay a dividend?
Albireo Pharma, Inc. (ALBO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALBO go public?
Albireo Pharma, Inc. (ALBO) completed its initial public offering in 2007.